Navigation Links
Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
Date:3/19/2008

CEDAR KNOLLS, N.J., March 19 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) released today results of additional animal studies demonstrating that its proprietary eligen(R) technology enhances the absorption of oral B12 at considerably lower doses than were used previously. The lower doses are believed to be more physiologically relevant. The data showed that the rate of absorption of B12 administered with eligen(R) increased significantly -- 26 to 34 minutes, compared with 72 minutes for B12 administered alone. Confirming the original study, overall absorption of B12 using eligen(R) technology was 18 times greater than with the same dose administered alone.

"This new data not only confirms our original findings, but is a step forward in our plan to commercialize our eligen(R) technology," said Michael V. Novinski, President and Chief Executive Officer of Emisphere. "These studies validate our belief in the efficacy of the technology and enable us to move toward human clinical studies as early as the beginning of the third quarter of this year."

Commenting on the size of the potential market for an oral B12 preparation, Mr. Novinski noted that, "there are at least five million people in the United States receiving 40 million B12 injections annually to treat a variety of debilitating medical conditions, and at least an additional five million people are consuming over 600 million tablets of B12 of various strengths annually. This indicates a large need for an oral B12 that can deliver therapeutic levels."

ABOUT EMISPHERE TECHNOLOGIES, INC.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical c
'/>"/>

SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
3. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... the "Company"), an international biopharmaceutical company with,operations in the U.S. and China , is pleased to announce the exercise of a,warrant by a principal shareholder, RimAsia Capital ... ... ... ...
(Date:3/18/2010)... March 18 EndoChoice, Inc. strengthens its ... launch of a new CEU program and a complete ... reprocessing.  "Incidents of pathogen transmission related to flexible endoscopy ... Institute continues to receive reports of potential endoscopy-related cross-contamination ...
(Date:3/17/2010)... Eli Lilly and Company (NYSE: LLY ) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut ... ... ... ...
Breaking Medicine Technology:NeoStem Announces Warrant Exercise by Principal Shareholder 2NeoStem Announces Warrant Exercise by Principal Shareholder 3NeoStem Announces Warrant Exercise by Principal Shareholder 4NeoStem Announces Warrant Exercise by Principal Shareholder 5EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products 2EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products 3Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 2Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 3Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 4Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 5Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 6Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 7Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 8YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 1YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 2YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 3YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 4Cellular Technology Extends the Boundaries of E healthcare Says Frost 26 Sullivan 50367 1Cellular Technology Extends the Boundaries of E healthcare Says Frost 26 Sullivan 50367 2Cellular Technology Extends the Boundaries of E healthcare Says Frost 26 Sullivan 50367 3Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market 50365 1Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market 50365 2Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market 50365 3
... commitment to hepatitis research , , ... (NYSE: SGP ) today provided a clinical ... protease inhibitor currently in Phase III development. The ... first-in-class and best-in-class protease inhibitor for treating chronic hepatitis ...
... GTHR.PK), announces it will soon begin offering its Real Time,PCR ... , GeneThera is set ... January of 2009. According to GeneThera Chairman, Dr. Tony ... PCR test for Johne,s disease,called HerdGuard(TM) by the first of ...
Other Medicine Technology:Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4
(Date:3/21/2010)... billion overhaul would give 31 million more Americans access ... -- Health experts say that the furiously debated $940 ... passage in Congress this weekend really boils down to ... health insurance. , "The big impact is the coverage ... 15 million people with incomes below 133 percent of ...
(Date:3/21/2010)... are big winners in the comprehensive healthcare reform package that the House is expected to approve today, according to Congressman Chaka Fattah ... ... ... ... ...
(Date:3/18/2010)... , ... Newborn’s Life and Still Afford Flowers for your Mom , ... Westport, CT (Vocus) March 18, 2010 -- This Mother’s Day, Save the Children ... of the poorest, most remote communities in the world. For as little as $13 you ...
(Date:3/18/2010)... ... ... ... Kids in New Jersey will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide for the ...
(Date:3/18/2010)... ... ... ... ROCHESTER, Minn. , March 18 "A good night,s sleep" has long been the intention of millions of people suffering from sleep disorders around the world. ...
Breaking Medicine News(10 mins):Health News:Showdown Over Health-Care Reform Bill Nears 2Health News:Showdown Over Health-Care Reform Bill Nears 3Health News:Showdown Over Health-Care Reform Bill Nears 4Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 2Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 3Health News:A Mother's Day Gift that Gives Lasting Joy 2Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:Sleep Well, Stay Healthy: Good Quality and Restorative Sleep Are Essential for Better Mental and Physical Health 2Health News:Sleep Well, Stay Healthy: Good Quality and Restorative Sleep Are Essential for Better Mental and Physical Health 3Health News:Sleep Well, Stay Healthy: Good Quality and Restorative Sleep Are Essential for Better Mental and Physical Health 4
... CHICAGO and GREENSBURG, Pa., Jan. 8 Allscripts,announced ... network serving,Western Pennsylvania, has selected the Allscripts Enterprise ... physicians it employs in the Excela Health,Physician Practices ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) , ...
... been followed for about 15 years , , THURSDAY, Jan. ... woman,s risk of colorectal cancer, especially if she is ... published in the January issue of Cancer Epidemiology, ... picture of the risks and benefits of hormone replacement ...
... TEAC America, Inc. launches its,next generation P-55C dye-sublimation ... available, during the CES Show at,the Las Vegas Convention ... The P-55C printer can be integrated with 3 TEAC ... With TEAC,s,AL220S and AL550S, customers can print up to ...
... REDWOOD CITY, Calif., Jan. 8 Genomic Health,Inc. (Nasdaq: ... Kimberly J. Popovits as,chief executive officer. Formerly president ... CEO of Genomic Health. In addition, G.,Bradley Cole ... continue,to serve as the company,s chief financial officer, reporting ...
... force hospitals to reconsider or defer purchases of ... Mass., Jan. 8 According to Millennium Research ... and CVIS 2009 report, the budgetary constraints ... the markets for picture archiving and communication systems ...
... Cardinal Health today,announced it expects to report solid earnings ... provided caution for the remainder of the fiscal,year because ... Clinical,and Medical Products segment. , ... second quarter, ended Dec. 31, 2008, is anticipated to ...
Other Medicine News:Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 2Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 3Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 4Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 5Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2Health News:Cardinal Health Updates FY09 Outlook 2Health News:Cardinal Health Updates FY09 Outlook 3Health News:Cardinal Health Updates FY09 Outlook 4Health News:Cardinal Health Updates FY09 Outlook 5
Scoville Hemilaminectomy Retractor...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
... Bone Graft represents an rhBMP-2 (recombinant human ... a bovine-derived absorbable collagen sponge (ACS) carrier. ... device is indicated for spinal fusion procedures ... disease (DDD) at one level from L4-S1, ...
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: